Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.33 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120790 | 0.85 | — | — | |
| SCHEMBL9547880 | 0.80 | TSHR (0.43) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL55033 | 0.76 | TSHR (0.53) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL3632705 | 0.74 | — | — | |
| SCHEMBL2121156 | 0.74 | — | — | |
| SCHEMBL9547965 | 0.73 | PTPN7 (0.43) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL2120933 | 0.73 | — | — | |
| SCHEMBL11854278 | 0.73 | TSHR (0.50) | TSHRPTPN7HMGCRRECQLTDP1 | |
| SCHEMBL6179604 | 0.71 | TSHR (0.36) | TSHR | |
| SCHEMBL157348 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114514223-B | Process for enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines comprising using novel iridium catalysts | 拜耳公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-0693284-A1 | PROSTACYCLIN-CONTAINING OLEAGINOUS OINTMENT | TEIJIN LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | TSHR 4076/4885PTPN7 601/4885HMGCR 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.